We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-1.18%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$509M
AUM Growth
-$864K
Cap. Flow
+$29.1M
Cap. Flow %
5.72%
Top 10 Hldgs %
50.89%
Holding
58
New
16
Increased
12
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$20.6M
2
CYTK icon
Cytokinetics
CYTK
+$20.4M
3
ANAB icon
AnaptysBio
ANAB
+$19.2M
4
EOLS icon
Evolus
EOLS
+$18.1M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$14.4M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$20.6M
2
VTYX
Ventyx Biosciences
VTYX
+$13.1M
3
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$12.5M
4
PTCT icon
PTC Therapeutics
PTCT
+$11.5M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.46M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLRX icon
1
Pliant Therapeutics
PLRX
$64.4M
$32.2M 6.33%
1,212,096
-110,774
-8% -$3.15M
XENE icon
2
Xenon Pharmaceuticals
XENE
$6.06B
$29.3M 5.75%
818,505
-31,495
-4% -$1.16M
ALPN
3
DELISTED
Alpine Immune Sciences Inc
ALPN
$28.9M 5.67%
3,740,761
+103,043
+3% +$821K
RARE icon
4
Ultragenyx Pharmaceutical
RARE
$2.45B
$27.2M 5.33%
677,426
+335,126
+98% +$14.4M
RAPT
5
DELISTED
RAPT Therapeutics
RAPT
$24.9M 4.88%
169,394
-10,177
-6% -$2.06M
PCVX icon
6
Vaxcyte
PCVX
$7.81B
$24.7M 4.85%
659,211
-140,789
-18% -$5.97M
PNT
7
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$24.6M 4.83%
3,383,029
+841,250
+33% +$6.24M
AMLX icon
8
Amylyx Pharmaceuticals
AMLX
$2.26B
$23M 4.52%
783,795
+593,795
+313% +$20.6M
TVTX icon
9
Travere Therapeutics
TVTX
$5.2B
$22.6M 4.43%
1,003,000
+528,000
+111% +$11.2M
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$15.9B
$21.9M 4.3%
149,500
-10,500
-7% -$1.55M
EOLS icon
11
Evolus
EOLS
$385M
$18.6M 3.64%
2,192,816
+2,002,487
+1,052% +$18.1M
CYTK icon
12
Cytokinetics
CYTK
$10.5B
$17.6M 3.45%
+500,000
New +$20.4M
ANAB icon
13
AnaptysBio
ANAB
$1.58B
$17.5M 3.44%
804,333
+789,333
+5,262% +$19.2M
ISEE
14
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$16.9M 3.32%
694,009
-130,991
-16% -$2.87M
VKTX icon
15
Viking Therapeutics
VKTX
$3.7B
$16.6M 3.27%
1,000,000
-295,034
-23% -$3.05M
JBIO
16
Jade Biosciences
JBIO
$1.2B
$15.2M 2.99%
21,589
+10,774
+100% +$8.94M
OPTN
17
DELISTED
OptiNose
OPTN
$15.2M 2.99%
526,316
– –
IMCR icon
18
Immunocore
IMCR
$1.72B
$12.6M 2.48%
+255,367
New +$14.4M
KALV
19
DELISTED
KalVista Pharmaceuticals
KALV
$12.6M 2.47%
1,600,545
+544,744
+52% +$4.06M
RLAY icon
20
Relay Therapeutics
RLAY
$4.1B
$10.8M 2.13%
+658,127
New +$11.8M
MLYS icon
21
Mineralys Therapeutics
MLYS
$2.25B
$9.71M 1.91%
+620,326
New +$10.4M
ACRS icon
22
Aclaris Therapeutics
ACRS
$726M
$9.64M 1.89%
1,191,581
+172,299
+17% +$2.19M
HRTX icon
23
Heron Therapeutics
HRTX
$93.9M
$8.78M 1.72%
5,817,368
-542,793
-9% -$1.36M
ACLX
24
DELISTED
Arcellx
ACLX
$7.92M 1.55%
+257,006
New +$7.8M
DTIL icon
25
Precision BioSciences
DTIL
$180M
$6.1M 1.2%
269,993
+143,283
+113% +$4.72M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Great Point Partners held 58 positions worth $509M, down 0.17% from $510M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Great Point Partners deployed $29.1M of net new capital in Q1 2023, opening 16 new positions and adding to 12 existing holdings. Its largest new stake was Cytokinetics: 500,000 shares worth $17.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Cymabay Therapeutics, an estimated $8.35M trimmed.

  • Great Point Partners's largest Q1 2023 buy was Cytokinetics: 500,000 shares worth $17.6M.
  • Great Point Partners added most to Amylyx Pharmaceuticals in Q1 2023, an estimated $20.6M increase.
  • Great Point Partners's biggest Q1 2023 reduction was Cymabay Therapeutics, cutting an estimated $8.35M.
  • Great Point Partners fully exited Seagen Inc. Common Stock in Q1 2023, selling an estimated $20.6M.
  • Great Point Partners's ten largest holdings make up 51% of its $509M portfolio in Q1 2023.
  • Great Point Partners opened 16 new positions and closed 14 in Q1 2023.
  • Great Point Partners's portfolio value fell 0.17% quarter-over-quarter to $509M.

Based on Great Point Partners's 13F filing for Q1 2023, filed 15 May 2023.